Daniel Krappmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1264113/publications.pdf

Version: 2024-02-01

107 papers	10,885 citations	34105 52 h-index	30922 102 g-index
111 all docs	111 docs citations	111 times ranked	12553 citing authors

#	Article	IF	Citations
1	MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer. Molecular Cancer Research, 2022, 20, 373-386.	3.4	7
2	Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency. Journal of Clinical Immunology, 2022, 42, 634-652.	3.8	12
3	A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF-Î²B signaling in activated T cells. Cellular and Molecular Life Sciences, 2022, 79, 112.	5.4	11
4	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells. Science Signaling, 2022, 15, eabk3083.	3.6	3
5	Optimized CRISPR-Cas9-based Strategy for Complex Gene Targeting in Murine Embryonic Stem Cells for Germline Transmission. Bio-protocol, 2022, 12, .	0.4	0
6	Human immune disorder associated with homozygous hypomorphic mutation affecting MALT1B splice variant. Journal of Allergy and Clinical Immunology, 2021, 147, 775-778.e8.	2.9	13
7	Methods to Study CARD11-BCL10-MALT1 Dependent Canonical NF-Î²B Activation in Jurkat T Cells. Methods in Molecular Biology, 2021, 2366, 125-143.	0.9	1
8	A patent review of MALT1 inhibitors (2013-present). Expert Opinion on Therapeutic Patents, 2021, 31, 1079-1096.	5.0	15
9	TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease. Science Immunology, 2021, 6, eabh2095.	11.9	17
10	Use of Non-Natural Amino Acids for the Design and Synthesis of a Selective, Cell-Permeable MALT1 Activity-Based Probe. Journal of Medicinal Chemistry, 2020, 63, 3996-4004.	6.4	8
11	Classification and Nomenclature of Metacaspases and Paracaspases: No More Confusion with Caspases. Molecular Cell, 2020, 77, 927-929.	9.7	71
12	MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells. Cell Reports, 2019, 29, 873-888.e10.	6.4	22
13	Regulation of the endosomal SNX27-retromer by OTULIN. Nature Communications, 2019, 10, 4320.	12.8	34
14	Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABCâ€subtype diffuse large Bâ€cell lymphoma. Journal of Pathology, 2019, 248, 142-154.	4.5	8
15	Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. Nature Communications, 2019, 10, 2352.	12.8	68
16	Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation. Nature Communications, 2019, 10, 701.	12.8	57
17	GSK3Î² modulates NF-Î²B activation and RelB degradation through site-specific phosphorylation of BCL10. Scientific Reports, 2018, 8, 1352.	3.3	21
18	S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells. Leukemia, 2018, 32, 214-223.	7.2	25

#	Article	IF	Citations
19	BCL10-CARD11 Fusion Mimics an Active CARD11 Seed That Triggers Constitutive BCL10 Oligomerization and Lymphocyte Activation. Frontiers in Immunology, 2018, 9, 2695.	4.8	12
20	Molecular architecture and regulation of BCL10-MALT1 filaments. Nature Communications, 2018, 9, 4041.	12.8	47
21	MALT1 activation by TRAF6 needs neither BCL10 nor CARD11. Biochemical and Biophysical Research Communications, 2018, 506, 48-52.	2.1	12
22	Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. Journal of Biological Chemistry, 2018, 293, 13191-13203.	3.4	52
23	BCL10 â€“ Bridging CARDs to Immune Activation. Frontiers in Immunology, 2018, 9, 1539.	4.8	46
24	Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF-ÎºB activation. Molecular Immunology, 2017, 83, 147-153.	2.2	29
25	B-cell receptorâ€“driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood, 2017, 129, 333-346.	1.4	57
26	A Linear Diubiquitin-Based Probe for Efficient and Selective Detection of the Deubiquitinating Enzyme OTULIN. Cell Chemical Biology, 2017, 24, 1299-1313.e7.	5.2	41
27	Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma. Leukemia, 2017, 31, 602-613.	7.2	14
28	YOD1/TRAF6 association balances p62-dependent IL-1 signaling to NF-ÎºB. ELife, 2017, 6, .	6.0	48
29	Canonical NFâ€ÎºB signaling in hepatocytes acts as a tumorâ€suppressor in hepatitis B virus surface antigenâ€driven hepatocellular carcinoma by controlling the unfolded protein response. Hepatology, 2016, 63, 1592-1607.	7.3	51
30	Inhibition of Canonical NF-ÎºB Signaling by a Small Molecule Targeting NEMO-Ubiquitin Interaction. Scientific Reports, 2016, 6, 18934.	3.3	26
31	Oncogenic CARMA1 couples NF-ÎºB and Î²-catenin signaling in diffuse large B-cell lymphomas. Oncogene, 2016, 35, 4269-4281.	5.9	44
32	Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome. Biological Chemistry, 2016, 397, 1315-1333.	2.5	59
33	Alternative splicing of MALT1 controls signalling and activation of CD4+ T cells. Nature Communications, 2016, 7, 11292.	12.8	94
34	Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-ÎºB activation. Biochemical Journal, 2016, 473, 1759-1768.	3.7	62
35	Mechanisms of NF-ÎºB deregulation in lymphoid malignancies. Seminars in Cancer Biology, 2016, 39, 3-14.	9.6	24
36	Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome. ACS Medicinal Chemistry Letters, 2016, 7, 250-255.	2.8	10

#	Article	IF	Citations
37	Development of new Malt1 inhibitors and probes. Bioorganic and Medicinal Chemistry, 2016, 24, 3312-3329.	3.0	18
38	B-Cell Receptor Driven MALT1 Activity Regulates MYC Signaling in Mantle Cell Lymphoma. Blood, 2016, 128, 611-611.	1.4	0
39	Activity-Based Probes for Detection of Active MALT1 Paracaspase in Immune Cells and Lymphomas. Chemistry and Biology, 2015, 22, 129-138.	6.0	36
40	In Vitro Detection of NEMOâ€“Ubiquitin Binding Using DELFIA and Microscale Thermophoresis Assays. Methods in Molecular Biology, 2015, 1280, 311-320.	0.9	2
41	Detection of Recombinant and Cellular MALT1 Paracaspase Activity. Methods in Molecular Biology, 2015, 1280, 239-246.	0.9	2
42	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. Oncotarget, 2015, 6, 42232-42242.	1.8	31
43	Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. Journal of Neuroinflammation, 2014, 11, 124.	7.2	76
44	Mechanisms and consequences of constitutive NF-ÎºB activation in B-cell lymphoid malignancies. Oncogene, 2014, 33, 5655-5665.	5.9	112
45	Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote TH17 differentiation. Nature Immunology, 2014, 15, 1079-1089.	14.5	238
46	MALT 1 protease: equilibrating immunity versus tolerance. EMBO Journal, 2014, 33, 2740-2742.	7.8	7
47	AIP augments CARMA1-BCL10-MALT1 complex formation to facilitate NF-ÎºB signaling upon T cell activation. Cell Communication and Signaling, 2014, 12, 49.	6.5	21
48	Structural Analysis of Phenothiazine Derivatives as Allosteric Inhibitors of the MALT1 Paracaspase. Angewandte Chemie - International Edition, 2013, 52, 10384-10387.	13.8	70
49	Progressive stages of mitochondrial destruction caused by cell toxic bile salts. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 2121-2133.	2.6	62
50	The E3 Ligase Parkin Maintains Mitochondrial Integrity by Increasing Linear Ubiquitination of NEMO. Molecular Cell, 2013, 49, 908-921.	9.7	183
51	OTULIN Antagonizes LUBAC Signaling by Specifically Hydrolyzing Met1-Linked Polyubiquitin. Cell, 2013, 153, 1312-1326.	28.9	395
52	Shaping oncogenic NF-ÎºB activity in the nucleus. Blood, 2013, 122, 2146-2147.	1.4	4
53	MALT1 paracaspase: a unique protease involved in B-cell lymphomagenesis. International Journal of Hematologic Oncology, 2013, 2, 409-417.	1.6	2
54	Strukturelle Analyse von Phenothiazinâ€Derivaten als allosterische Inhibitoren der MALT1â€Paracaspase. Angewandte Chemie, 2013, 125, 10575-10579.	2.0	0

#	Article	IF	Citations
55	Measurement of Endogenous MALT1 Activity. Bio-protocol, 2013, 3, .	0.4	1
56	A20 and CYLD Do Not Share Significant Overlapping Functions during B Cell Development and Activation. Journal of Immunology, 2012, 189, 4437-4443.	0.8	24
57	Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL. Cancer Cell, 2012, 22, 825-837.	16.8	216
58	Attacking MALT1 for ABC-DLBCL therapy. Oncotarget, 2012, 3, 1489-1490.	1.8	1
59	Dlg3 Trafficking and Apical Tight Junction Formation Is Regulated by Nedd4 and Nedd4-2 E3ÂUbiquitin Ligases. Developmental Cell, 2011, 21, 479-491.	7.0	48
60	Dephosphorylation of Carma1 by PP2A negatively regulates T-cell activation. EMBO Journal, 2011, 30, 594-605.	7.8	60
61	NF-ÎºB Essential Modulator (NEMO) Interaction with Linear and Lys-63 Ubiquitin Chains Contributes to NF-ÎºB Activation. Journal of Biological Chemistry, 2011, 286, 26107-26117.	3.4	102
62	The Ca2+-dependent Phosphatase Calcineurin Controls the Formation of the Carma1-Bcl10-Malt1 Complex during T Cell Receptor-induced NF-ÎºB Activation. Journal of Biological Chemistry, 2011, 286, 7522-7534.	3.4	89
63	Critical role of PI3K signaling for NF-ÎºBâ€“dependent survival in a subset of activated B-cellâ€“like diffuse large B-cell lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 272-277.	7.1	127
64	Signals from the Nucleus: Activation of NF-ÎºB by Cytosolic ATM in the DNA Damage Response. Science Signaling, 2011, 4, pe2.	3.6	56
65	Ubiquitin Conjugation and Deconjugation in NF-ÎºB Signaling. Sub-Cellular Biochemistry, 2010, 54, 88-99.	2.4	10
66	A20 Negatively Regulates T Cell Receptor Signaling to NF-ÎºB by Cleaving Malt1 Ubiquitin Chains. Journal of Immunology, 2009, 182, 7718-7728.	0.8	222
67	Inhibition of MALT1 protease activity is selectively toxic for activated B cellâ€“like diffuse large B cell lymphoma cells. Journal of Experimental Medicine, 2009, 206, 2313-2320.	8.5	195
68	Role of Oxidative Stress in Ultrafine Particleâ€“induced Exacerbation of Allergic Lung Inflammation. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 984-991.	5.6	90
69	Inhibition of MALT1 protease activity is selectively toxic for activated B cellâ€“like diffuse large B cell lymphoma cells. Journal of Experimental Medicine, 2009, 206, 2851-2851.	8.5	2
70	COP9 signalosome controls the Carma1â€“Bcl10â€“Malt1 complex upon Tâ€cell stimulation. EMBO Reports, 2009, 10, 642-648.	4.5	31
71	The let-7 target gene mouse lin-41 is a stem cell specific E3 ubiquitin ligase for the miRNA pathway protein Ago2. Nature Cell Biology, 2009, 11, 1411-1420.	10.3	211
72	Inhibition of MALT1 Protease Activity Is Selectively Toxic for Activated B CellÀƒ‚Ì,Ã‚â€“Like Diffuse Large B Cell Lymphoma Cells.. Blood, 2009, 114, 1271-1271.	1.4	0

#	Article	IF	Citations
73	Distinct isocomplexes of the TRAPP trafficking factor coexist inside human cells. FEBS Letters, 2008, 582, 3729-3733.	2.8	22
74	Parkin Mediates Neuroprotection through Activation of IÂB Kinase/Nuclear Factor-ÂB Signaling. Journal of Neuroscience, 2007, 27, 1868-1878.	3.6	171
75	CARD-Bcl10-Malt1 Signalosomes: Missing Link to NF-ÎºB. Science's STKE: Signal Transduction Knowledge Environment, 2007, 2007, pe21.	3.9	60
76	MALT1 directs B cell receptorâ€“induced canonical nuclear factor-ÎºB signaling selectively to the c-Rel subunit. Nature Immunology, 2007, 8, 984-991.	14.5	78
77	Malt1 ubiquitination triggers NF-ÎºB signaling upon T-cell activation. EMBO Journal, 2007, 26, 4634-4645.	7.8	189
78	Essential Role for IÎºB Kinase Î² in Remodeling Carma1-Bcl10-Malt1 Complexes upon T Cell Activation. Molecular Cell, 2006, 23, 13-23.	9.7	117
79	Controlling NF-ÎºB activation in T cells by costimulatory receptors. Cell Death and Differentiation, 2006, 13, 834-842.	11.2	50
80	A pervasive role of ubiquitin conjugation in activation and termination of IÎºB kinase pathways. EMBO Reports, 2005, 6, 321-326.	4.5	105
81	Viral targeting of the interferon-Î²-inducing Traf family member-associated NF-ÎºB activator (TANK)-binding kinase-1. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13640-13645.	7.1	102
82	Degradation of Bcl10 Induced by T-Cell Activation Negatively Regulates NF-ÎºB Signaling. Molecular and Cellular Biology, 2004, 24, 3860-3873.	2.3	135
83	The IÎºB Kinase Complex and NF-ÎºB Actas Master Regulators of Lipopolysaccharide-Induced Gene Expressionand Control Subordinate Activation ofAP-1. Molecular and Cellular Biology, 2004, 24, 6488-6500.	2.3	152
84	Requirement of Hsp90 activity for IÎºB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-ÎºB activation. Oncogene, 2004, 23, 5378-5386.	5.9	208
85	Lymphotoxin and lipopolysaccharide induce NFâ€ÎºBâ€p52 generation by a coâ€translational mechanism. EMBO Reports, 2003, 4, 82-87.	4.5	118
86	Purification and Characterization of the Human Elongator Complex. Journal of Biological Chemistry, 2002, 277, 3047-3052.	3.4	230
87	Nuclear Factor ÎºBâ€“dependent Gene Expression Profiling of Hodgkin's Disease Tumor Cells, Pathogenetic Significance, and Link to Constitutive Signal Transducer and Activator of Transcription 5a Activity. Journal of Experimental Medicine, 2002, 196, 605-617.	8.5	244
88	Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappaB. EMBO Journal, 2002, 21, 4104-4113.	7.8	323
89	Tissue-Specific Expression of a Splicing Mutation in the Gene Causes Familial Dysautonomia. American Journal of Human Genetics, 2001, 68, 598-605.	6.2	558
90	Constitutive NF-ÎºB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood, 2001, 97, 2798-2807.	1.4	246

#	Article	IF	Citations
91	In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-ÎºB activity. Leukemia, 2001, 15, 921-928.	7.2	80
92	B-Cell Receptor- and Phorbol Ester-Induced NF-ÎºB and c-Jun N-Terminal Kinase Activation in B Cells Requires Novel Protein Kinase C's. Molecular and Cellular Biology, 2001, 21, 6640-6650.	2.3	78
93	Shared Pathways of IÎºB Kinase-Induced SCF Î²TrCP -Mediated Ubiquitination and Degradation for the NF-ÎºB Precursor p105 and IÎºBÎ±. Molecular and Cellular Biology, 2001, 21, 1024-1035.	2.3	133
94	NF- Îº B and the innate immune response. Current Opinion in Immunology, 2000, 12, 52-58.	5.5	323
95	Transcription factor NF-ÎºB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia, 2000, 14, 399-402.	7.2	252
96	The IÎºB Kinase (IKK) Complex Is Tripartite and Contains IKKÎ³ but Not IKAP as a Regular Component. Journal of Biological Chemistry, 2000, 275, 29779-29787.	3.4	105
97	Overexpression of I Kappa B Alpha Without Inhibition of NF-ÎºB Activity and Mutations in the I Kappa B Alpha Gene in Reed-Sternberg Cells. Blood, 1999, 94, 3129-3134.	1.4	249
98	NF-ÎºB Function in Growth Control: Regulation of Cyclin D1 Expression and G₀/G₁-to-S-Phase Transition. Molecular and Cellular Biology, 1999, 19, 2690-2698.	2.3	745
99	Molecular mechanisms of constitutive NF-ÎºB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene, 1999, 18, 943-953.	5.9	265
100	NF-kappa B p105 is a target of Ikappa B kinases and controls signal induction of Bcl-3-p50 complexes. EMBO Journal, 1999, 18, 4766-4778.	7.8	184
101	Overexpression of I Kappa B Alpha Without Inhibition of NF-ÎºB Activity and Mutations in the I Kappa B Alpha Gene in Reed-Sternberg Cells. Blood, 1999, 94, 3129-3134.	1.4	21
102	Signal-dependent degradation of IÂBÂ is mediated by an inducible destruction box that can be transferred to NF-ÂB, Bcl-3 or p53. Nucleic Acids Research, 1998, 26, 1724-1730.	14.5	18
103	Regulation of NF-ÎºB activity by IÎºBÎ± and IÎºBÎ² Stability. Immunobiology, 1997, 198, 3-13.	1.9	38
104	Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.. Journal of Clinical Investigation, 1997, 100, 2961-2969.	8.2	699
105	The NF-ÎºB/Rel and IÎºB gene families: mediators of immune response and inflammation. Journal of Molecular Medicine, 1996, 74, 749-769.	3.9	235
106	Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo.. EMBO Journal, 1996, 15, 6716-6726.	7.8	178
107	High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood, 1996, 87, 4340-4347.	1.4	309